Literature DB >> 19701232

n-Butylidenephthalide induced apoptosis in the A549 human lung adenocarcinoma cell line by coupled down-regulation of AP-2alpha and telomerase activity.

Chyou-wei Wei1, Chai-ching Lin, Yung-luen Yu, Chai-yi Lin, Po-cheng Lin, Min-tze Wu, Cheng-jueng Chen, Wenliang Chang, Shinn-zong Lin, Yi-lin Sophia Chen, Horng-jyh Harn.   

Abstract

AIM: To investigate the role of hTERT gene expression and AP-2alpha in n-butylidenephthalide (n-BP)-induced apoptosis in A549 lung cancer cells.
METHODS: Viability of A549 cells was measured by MTT assay. Protein expression was determined by Western blot. Telomerase activity was measured using the modified telomere repeat amplification protocol (TRAP) assay. Xenograft mice were used as a model system to study the cytotoxic effect of n-BP in vivo. The morphology of tumor was examined by immunohistochemical staining.
RESULTS: The growth of A549 lung cancer cells treated with n-BP was significantly inhibited. Telomerase activity and hTERT mRNA expression were determined by telomeric repeat amplification protocol and reverse transcription-polymerase chain reaction, respectively. n-BP inhibited telomerase activity and hTERT mRNA expression in A549 cells while overexpression of hTERT could abolish BP-induced growth inhibition in the A549 cells. We also showed that hTERT promoter activity in the presence of n-BP was mediated via AP-2alpha. We saw an inhibition of tumor growth when nude mice carrying A549 subcutaneous xenograft tumors were treated with n-BP. Immunohistochemistry of this tumor tissue also showed a decrease in the expression of hTERT.
CONCLUSION: The antiproliferative effects of n-BP on A549 cells in vitro and in vivo suggest a novel clinical application of this compound in the treatment of lung cancers.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19701232      PMCID: PMC4007174          DOI: 10.1038/aps.2009.124

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  40 in total

1.  Telomerase reverse transcriptase promoter regulation during myogenic differentiation of human RD rhabdomyosarcoma cells.

Authors:  Hongwen Ma; Virginia Urquidi; Jeremy Wong; Jeanine Kleeman; Steve Goodison
Journal:  Mol Cancer Res       Date:  2003-08       Impact factor: 5.852

Review 2.  Structure and function of telomeres.

Authors:  E H Blackburn
Journal:  Nature       Date:  1991-04-18       Impact factor: 49.962

3.  A telomeric sequence in the RNA of Tetrahymena telomerase required for telomere repeat synthesis.

Authors:  C W Greider; E H Blackburn
Journal:  Nature       Date:  1989-01-26       Impact factor: 49.962

4.  Reduced nuclear expression of transcription factor AP-2 associates with aggressive breast cancer.

Authors:  Johanna Pellikainen; Vesa Kataja; Kirsi Ropponen; Jari Kellokoski; Timo Pietiläinen; Jan Böhm; Matti Eskelinen; Veli-Matti Kosma
Journal:  Clin Cancer Res       Date:  2002-11       Impact factor: 12.531

5.  Evaluation of telomerase in the development and progression of colon cancer.

Authors:  L Boldrini; P Faviana; S Gisfredi; Y Zucconi; D Di Quirico; V Donati; P Berti; R Spisni; D Galleri; G Materazzi; F Basolo; P Miccoli; R Pingitore; G Fontanini
Journal:  Int J Mol Med       Date:  2002-11       Impact factor: 4.101

6.  Expression of HER2 and its association with AP-2 in breast cancer.

Authors:  J Pellikainen; A Naukkarinen; K Ropponen; J Rummukainen; V Kataja; J Kellokoski; M Eskelinen; V-M Kosma
Journal:  Eur J Cancer       Date:  2004-07       Impact factor: 9.162

Review 7.  On the road to immortality: hTERT upregulation in cancer cells.

Authors:  Ralf Janknecht
Journal:  FEBS Lett       Date:  2004-04-23       Impact factor: 4.124

8.  Hypermethylation of a small CpGuanine-rich region correlates with loss of activator protein-2alpha expression during progression of breast cancer.

Authors:  Donna B Douglas; Yoshimitsu Akiyama; Hetty Carraway; Steven A Belinsky; Manel Esteller; Edward Gabrielson; Sigmund Weitzman; Trevor Williams; James G Herman; Stephen B Baylin
Journal:  Cancer Res       Date:  2004-03-01       Impact factor: 12.701

9.  Inhibition of the epidermal growth factor receptor suppresses telomerase activity in HSC-1 human cutaneous squamous cell carcinoma cells.

Authors:  Arief Budiyanto; Toshinori Bito; Makoto Kunisada; Masashi Ashida; Masamitsu Ichihashi; Masato Ueda
Journal:  J Invest Dermatol       Date:  2003-11       Impact factor: 8.551

10.  Activator protein 2alpha inhibits tumorigenicity and represses vascular endothelial growth factor transcription in prostate cancer cells.

Authors:  Maribelis Ruiz; Curtis Pettaway; Renduo Song; Oliver Stoeltzing; Lee Ellis; Menashe Bar-Eli
Journal:  Cancer Res       Date:  2004-01-15       Impact factor: 12.701

View more
  24 in total

1.  Induction of apoptosis coupled to endoplasmic reticulum stress in human prostate cancer cells by n-butylidenephthalide.

Authors:  Sheng-Chun Chiu; Shee-Ping Chen; Sung-Ying Huang; Mei-Jen Wang; Shinn-Zong Lin; Horng-Jyh Harn; Cheng-Yoong Pang
Journal:  PLoS One       Date:  2012-03-28       Impact factor: 3.240

2.  Downregulation of DAB2IP promotes mesenchymal-to-neuroepithelial transition and neuronal differentiation of human mesenchymal stem cells.

Authors:  Sunny Li-Yun Chang; Ruey-Hwang Chou; Hong-Jie Zeng; Yu-Hsuan Lin; Tai-Yu Chiu; De-Ming Yang; Shih-Chieh Hung; Chih-Ho Lai; Jer-Tsong Hsieh; Woei-Cherng Shyu; Yung-Luen Yu
Journal:  PLoS One       Date:  2013-09-20       Impact factor: 3.240

3.  n-butylidenephthalide protects against dopaminergic neuron degeneration and α-synuclein accumulation in Caenorhabditis elegans models of Parkinson's disease.

Authors:  Ru-Huei Fu; Horng-Jyh Harn; Shih-Ping Liu; Chang-Shi Chen; Wen-Lin Chang; Yue-Mi Chen; Jing-En Huang; Rong-Jhu Li; Sung-Yu Tsai; Huey-Shan Hung; Woei-Cherng Shyu; Shinn-Zong Lin; Yu-Chi Wang
Journal:  PLoS One       Date:  2014-01-08       Impact factor: 3.240

4.  Selaginella tamariscina extract suppresses TPA-induced invasion and metastasis through inhibition of MMP-9 in human nasopharyngeal carcinoma HONE-1 cells.

Authors:  Chung-Han Hsin; Buor-Chang Wu; Chun-Yi Chuang; Shun-Fa Yang; Yi-Hsien Hsieh; Hsin-Yu Ho; Huang-Pin Lin; Mu-Kuan Chen; Chiao-Wen Lin
Journal:  BMC Complement Altern Med       Date:  2013-09-23       Impact factor: 3.659

5.  Dual role of acetaminophen in promoting hepatoma cell apoptosis and kidney fibroblast proliferation.

Authors:  Yung-Luen Yu; Giou-Teng Yiang; Pei-Lun Chou; Hsu-Hung Tseng; Tsai-Kun Wu; Yu-Ting Hung; Pei-Shiuan Lin; Shu-Yu Lin; Hsiao-Chun Liu; Wei-Jung Chang; Chyou-Wei Wei
Journal:  Mol Med Rep       Date:  2014-03-28       Impact factor: 2.952

6.  Liposomal n-butylidenephthalide protects the drug from oxidation and enhances its antitumor effects in glioblastoma multiforme.

Authors:  Yu-Ling Lin; Kai-Fu Chang; Xiao-Fan Huang; Che-Lun Hung; Shyh-Chang Chen; Wan-Ru Chao; Kuang-Wen Liao; Nu-Man Tsai
Journal:  Int J Nanomedicine       Date:  2015-09-28

7.  Impacts of CA9 gene polymorphisms on urothelial cell carcinoma susceptibility and clinicopathologic characteristics in Taiwan.

Authors:  Shian-Shiang Wang; Yu-Fan Liu; Yen-Chuan Ou; Chuan-Shu Chen; Jian-Ri Li; Shun-Fa Yang
Journal:  PLoS One       Date:  2013-12-13       Impact factor: 3.240

8.  MicroRNA gene polymorphisms and environmental factors increase patient susceptibility to hepatocellular carcinoma.

Authors:  Yin-Hung Chu; Ming-Ju Hsieh; Hui-Ling Chiou; Yi-Sheng Liou; Chen-Chieh Yang; Shun-Fa Yang; Wu-Hsien Kuo
Journal:  PLoS One       Date:  2014-02-26       Impact factor: 3.240

9.  Licochalcone A suppresses migration and invasion of human hepatocellular carcinoma cells through downregulation of MKK4/JNK via NF-κB mediated urokinase plasminogen activator expression.

Authors:  Jen-Pi Tsai; Pei-Ching Hsiao; Shun-Fa Yang; Shu-Ching Hsieh; Da-Tian Bau; Chu-Liang Ling; Chun-Li Pai; Yi-Hsien Hsieh
Journal:  PLoS One       Date:  2014-01-22       Impact factor: 3.240

10.  Vitamin C enhances anticancer activity in methotrexate‑treated Hep3B hepatocellular carcinoma cells.

Authors:  Giou-Teng Yiang; Pei-Lun Chou; Yu-Ting Hung; Jen-Ni Chen; Wei-Jung Chang; Yung-Luen Yu; Chyou-Wei Wei
Journal:  Oncol Rep       Date:  2014-06-25       Impact factor: 3.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.